Summary & Overview
HCPCS G0465: Autologous PRP for Diabetic Chronic Wounds
HCPCS Level II code G0465 covers the use of autologous platelet rich plasma (PRP) or other blood-derived products for treatment of diabetic chronic wounds and ulcers when delivered with an FDA-cleared device. This code is significant nationally as diabetic foot ulcers and chronic wounds are high-cost, high-utilization conditions where advanced biologic therapies may affect healing time, downstream complications, and overall episode costs. Payers use this code to identify and manage claims for device-cleared, per-treatment PRP wound therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for PRP in diabetic wounds, payer coverage patterns and benchmarking (when available), common billing considerations, and policy updates relevant to device-cleared blood-derived product therapies. The publication outlines service settings where G0465 is typically billed and summarizes what constitutes an included per-treatment bundle under the code description.
This briefing is written for a national audience and is intended to clarify code intent, sites of service, and the type of service activity captured by G0465, enabling payers, providers, and policy stakeholders to align documentation and claim submission practices.
Billing Code Overview
HCPCS Level II code G0465 describes autologous platelet rich plasma (PRP) or other blood-derived product used specifically for diabetic chronic wounds/ulcers, delivered with an FDA-cleared device for this indication. The code includes, as applicable, administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment.
Service Type: Biologic wound therapy / blood-derived product administration
Typical Site of Service: Outpatient wound care clinics, specialty wound centers, hospital outpatient departments, and ambulatory surgical centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with long-standing type 2 diabetes mellitus and peripheral neuropathy presents to a wound care clinic for evaluation of a nonhealing plantar foot ulcer present for 10 weeks despite standard care (debridement, offloading, moist dressings, and topical antimicrobials). Wound measurement shows a 2.4 cm diameter full-thickness ulcer without exposed bone, signs of ischemia, or acute infection. The multidisciplinary wound care team (podiatry or wound care physician and a certified wound care nurse) determines the patient is an appropriate candidate for autologous platelet-rich plasma (PRP) therapy using an FDA-cleared device for diabetic chronic wounds.
Clinical workflow:
-
Initial evaluation and documentation of wound history, size, depth, circulation, and neuropathy.
-
Baseline photography and measurement; obtain informed consent specific to autologous blood-derived product application.
-
Phlebotomy performed in clinic; blood processed via FDA-cleared centrifuge/mixing device to derive PRP per manufacturer instructions.
-
Wound bed preparation (sharp or mechanical debridement as indicated) and irrigation.
-
Application/administration of autologous PRP to the wound; placement of appropriate primary and secondary dressings.
-
Post-procedure instructions and schedule for follow-up visits for dressing changes, repeat treatments (per payer or device guidance), and reassessment of wound healing progress.
-
Documentation includes device used (FDA-cleared for diabetic chronic wounds), volume of blood drawn, processing steps (centrifugation), administration, and any immediate adverse events.